Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06803589 · ClinicalTrials.gov registry record · Early Phase 1
Growth Hormone for the Treatment of Gastroparesis
A Early Phase 1 study of Gastroparesis, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
- 2
- Study locations
NCT06803589: Recruiting Early Phase 1 study of Gastroparesis, sponsored by Mayo Clinic.
NCT06803589 is a Early Phase 1 study of Gastroparesis that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 10 participants, below the 302-participant average among 44 other Gastroparesis trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06803589, a Early Phase 1 study of Gastroparesis, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to determine whether treatment with Growth Hormone results in symptomatic improvement in patients with gastroparesis.
Primary Outcome
The Gastroparesis Cardinal Symptom Index (GCSI) is a questionnaire that assesses the severity of gastroparesis symptoms of: nausea, early satiety, postprandial fullness, and upper abdominal pain. Scores range from 0-none to 4-very severe.
Conditions Studied
Interventions
- DRUG Growth Hormone
Study Locations (2)
Arizona
- Mayo Clinic - Phoenix
- Mayo Clinic in Arizona - Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2024-10-22 |
| Est. Completion | 2027-12 |
| Phase | Early Phase 1 |
What NCT06803589 shows while recruiting
NCT06803589 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 302-participant average among 44 other Gastroparesis trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Gastroparesis appearing as the primary indexed condition, and to 1 intervention - of which Growth Hormone is the first listed.
NCT06803589 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT06803589 about?
NCT06803589 is a clinical study titled "Growth Hormone for the Treatment of Gastroparesis". The purpose of this study is to determine whether treatment with Growth Hormone results in symptomatic improvement in patients with gastroparesis.
What is the current status of trial NCT06803589?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2024-10-22. Estimated completion is 2027-12.
What conditions does trial NCT06803589 study?
This clinical trial studies the following conditions: Gastroparesis.
What interventions are being tested in trial NCT06803589?
The interventions under investigation include: Growth Hormone (DRUG).
Who is sponsoring clinical trial NCT06803589?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06803589 being conducted?
This trial has 2 study locations across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastroparesis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06803589's enrollment target sits among peer trials
10 41st of 44 higher than 2 of 44 other Gastroparesis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gastroparesis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pioglitazone for Idiopathic Gastroparesis
COMPLETED · Early Phase 1
-
Gastroparesis Registry 4
RECRUITING
-
The Use of Body Surface Gastric Mapping in Assessing the Clinical Success of G-POEM
RECRUITING · NA
-
Study of Gastric Motility in Eosinophilic Gastritis
RECRUITING
-
Indiana University Gastrointestinal Motility Diagnosis Registry
RECRUITING
-
Compassionate Use of Domperidone for Refractory Gastroparesis
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI